Associated tags: Patient, Therapy, Cancer, SAN, Pharmaceutical industry, CD22, CAR, MD, CD19, Doctor of Philosophy, Research, B-cell lymphoma
Locations: EUROPE, EUROPEAN UNION, TD, NEW YORK, SAN MATEO, CA, US, CAR, RUSSELL, CR
Diamond,
Cancer,
Eli Lilly,
B-cell lymphoma,
Biologics license application,
MD Anderson Cancer Center,
Therapy,
University,
Patient,
Eli Lilly and Company,
BLA,
Health,
Drug development,
Biotechnology,
SAN,
Head,
Pharmaceutical industry Dr. Dhingra’s development experience spans several oncology companies, both as a Board member or in senior leadership.
Key Points:
- Dr. Dhingra’s development experience spans several oncology companies, both as a Board member or in senior leadership.
- He is currently Chairman of the Board for LAVA Therapeutics, a member of the Board of Supervisors for Servier and a member of the Board of Directors of Black Diamond Therapeutics, Inc., Replimune, Inc., and Median Technologies.
- He previously served on the Board of Autolus Therapeutics plc from the company’s inception until the recent Biologics License Application (BLA) filing of its CAR T-cell therapy.
- “We are pleased to welcome Dr. Dhingra to our Board,” said Gina Chapman, President and Chief Executive Officer, CARGO Therapeutics.
Research,
B-cell lymphoma,
Disease,
Patient,
SAN,
G&A,
Cancer,
IPO,
Stanford University,
Trial of the century,
Therapy,
Safety,
CD19,
Pharmaceutical industry SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year ending December 31, 2023.
Key Points:
- CARGO had $405.7 million in cash and cash equivalents as of December 31, 2023, which it expects will fund operations through 2025.
- Research and development (R&D) expenses were $27.1 million for the fourth quarter of 2023, which includes $0.7 million of non-cash stock-based compensation expense.
- General and administrative (G&A) expenses were $7.9 million for the fourth quarter of 2023, which includes $1.0 million of non-cash stock-based compensation expense.
- For 2023, net loss was $98.1 million, or $16.53 per share, including non-cash stock-based compensation and depreciation expenses of $3.3 million and $1.5 million, respectively.
Retrieved on:
Thursday, February 29, 2024
SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, Massachusetts.
Key Points:
- SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, Massachusetts.
- Gina Chapman, President and Chief Executive Officer, is scheduled to participate in a cell therapy corporate panel discussion on Wednesday, March 6, at 9:10 a.m. EST.
- A live webcast of the panel discussion will be accessible through the Investors section of CARGO’s website under News & Events .
- A replay of the webcast will be available after the conclusion of the live presentation for 30 days.
Retrieved on:
Wednesday, January 3, 2024
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.
Key Points:
- SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.
- Gina Chapman, President and Chief Executive Officer, is scheduled to present on Monday, January 8, at 9:45 AM PT.
- Interested parties can access the live webcast for the presentation in the Investors section of CARGO’s website under News & Events .
- A replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days.
Retrieved on:
Wednesday, December 13, 2023
Clinical trial,
Stanford University,
Conference,
Survival,
Lymphoid leukemia,
Relapse,
Research,
Disease,
MD,
Doctor of Philosophy,
SAN,
Society,
Therapy,
Cancer,
ASH,
Annual general meeting,
Death,
Growth,
IPO,
CD19,
Safety,
OS,
G&A,
CD22,
B-cell lymphoma,
Pharmacology,
Pharmaceutical industry SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported business updates and its financial results for the third quarter ended September 30, 2023.
Key Points:
- SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported business updates and its financial results for the third quarter ended September 30, 2023.
- Net loss was $35.5 million, or $47.37 per basic and diluted share, for the quarter ended September 30, 2023.
- This compares with a net loss of $12.3 million, or $28.38 per basic and diluted share for the quarter ended September 30, 2022.
- CARGO will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.
Retrieved on:
Wednesday, December 6, 2023
Associate,
Baylor University,
Baylor College of Medicine,
Hospital,
Division,
Research,
Investment company,
Massachusetts General Hospital,
MD,
Doctor of Philosophy,
SAB,
SAN,
Therapy,
Cancer,
CD2,
Health,
Section,
Dana–Farber Cancer Institute,
University,
Hematology,
Faculty,
MBBS,
Royal North Shore Hospital,
Patient,
Boston,
Harvard Medical School,
MGH,
Medical school,
CD22,
Nursing SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.
Key Points:
- SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.
- The SAB will provide strategic counsel and critical expertise as CARGO advances its mission to develop the next generation of transformational CAR T-cell therapies.
- “The SAB stands out by bringing together several highly accomplished translational investigators each with CAR T-cell experience that bridges both the laboratory and the clinic,” said Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair.
- “They are uniquely suited to advise CARGO on their scientific goals and directions that will lead to better outcomes for patients.”
Members of the CARGO Scientific Advisory Board are listed below; full bios are available on the CARGO website .
Retrieved on:
Friday, November 10, 2023
Sale,
Madison Avenue,
Telephone,
Attention,
SAN,
Therapy,
Jefferies,
Lexington Avenue,
Patient,
Truist,
Jefferies Group,
Prospectus,
Cancer,
Security (finance) SAN MATEO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (“CARGO”), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the pricing of its initial public offering of 18,750,000 shares of its common stock at a public offering price of $15.00 per share.
Key Points:
- SAN MATEO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (“CARGO”), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the pricing of its initial public offering of 18,750,000 shares of its common stock at a public offering price of $15.00 per share.
- All of the shares of common stock are being offered by CARGO.
- The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by CARGO, are expected to be approximately $281.3 million.
- In addition, CARGO has granted the underwriters a 30-day option to purchase up to 2,812,500 additional shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
Retrieved on:
Tuesday, October 17, 2023
University,
Stanford Cancer Institute,
Antibody,
Monoclonal antibody,
Division,
Drug,
Research,
Trial of the century,
Stanford University School of Medicine,
MD,
Mosunetuzumab,
BLA,
IND,
Health,
Biotechnology,
Medicine,
Disease,
Cancer,
Patient,
BA,
Therapy,
B-cell lymphoma,
CAR,
NME,
CD22,
Publication,
SAN,
CD19,
BMT,
Acceleration,
Baylor University,
B Division (New York City Subway),
NIH,
Pharmaceutical industry,
Nursing,
Stanford University,
Blood SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer. Dr. Laport is a seasoned biotechnology executive and senior clinical leader. She will serve on the Company’s executive team and will be responsible for providing leadership and direction to guide CARGO’s clinical development strategy and execution, including the advancement of CARGO’s lead candidate, CRG-022, as well as its pipeline of next-generation CAR T-cell therapies for cancer patients. CRG-022 is an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, currently in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Key Points:
- SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer.
- “We are thrilled to announce the addition of Ginna to our team as Chief Medical Officer.
- With her extensive leadership background in clinical drug development, particularly in hematology/oncology, she brings invaluable expertise to our organization,” said Gina Chapman, CARGO’s President and Chief Executive Officer.
- Previously, Dr. Laport was Chief Medical Officer at Tempest Therapeutics, where she directed the clinical development of small molecules that combine both tumor-targeted and immune-mediated mechanisms, including several IND submissions.
Retrieved on:
Tuesday, September 12, 2023
Lymphoma,
Juno,
Gilead Sciences,
BS,
University,
B-cell lymphoma,
Therapy,
Multiple myeloma,
Netherlands Cancer Institute,
Cancer,
Janssen,
Fred Hutchinson Cancer Research Center,
University of California,
Research,
Bristol Myers Squibb,
Doctor of Philosophy,
CAR,
Developmental Biology (journal),
Documentation,
Patient,
SAN,
Celgene,
European,
Janssen Pharmaceuticals,
Cell,
Juno Therapeutics,
BLA,
IND,
Pharmaceutical industry SAN MATEO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Michael Ports, PhD, as Chief Scientific Officer. Dr. Ports will be responsible for advancing CARGO's proprietary platform technologies and discovery-stage programs.
Key Points:
- SAN MATEO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Michael Ports, PhD, as Chief Scientific Officer.
- “I am delighted to welcome Michael, an experienced leader in cell therapy, to CARGO as our Chief Scientific Officer.
- Michael brings strong scientific leadership and a deep understanding of cell therapy to this role and will be an inspiring thought partner to our research and development teams,” said Gina Chapman, CARGO's President and Chief Executive Officer.
- Throughout my career, I have sought opportunities to develop differentiated therapeutics and treatment strategies to significantly improve outcomes for patients,” said Michael Ports, Chief Scientific Officer, CARGO Therapeutics.
Retrieved on:
Thursday, August 24, 2023
Doctor of Pharmacy,
Pediatrics,
CD19,
Independent,
Stanford University,
Biotechnology,
Cancer,
Independent director,
Bristol Myers Squibb,
Genentech,
Sutro Biopharma,
Audit committee,
CAR,
MD,
Patient,
Celgene,
Series,
Drug discovery,
Rhône-Poulenc,
Entrepreneurship,
Johnson & Johnson,
BMS,
Therapy,
Management,
Pharmaceutical industry,
Medicine SAN MATEO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation CAR T-cell therapies designed to provide hope for a cure for more cancer patients, today announced the addition of independent directors to the Board of Directors following its recent $200 million Series A financing in March 2023. The Board brings together an esteemed group of experienced life science leaders with expertise spanning finance, business operations, drug discovery and clinical development, including experts and pioneers in CAR T-cell therapies and oncology.
Key Points:
- The Board brings together an esteemed group of experienced life science leaders with expertise spanning finance, business operations, drug discovery and clinical development, including experts and pioneers in CAR T-cell therapies and oncology.
- The most recent board appointments include John Orwin as Chairman of the Board, David Lubner as Independent Director and Strategic Finance and Audit Committee Chair, and Krishnan Viswanadhan, PharmD, as Independent Director.
- During his time at BMS, he oversaw the teams responsible for the development, approval and life cycle management of commercial CAR T therapies.
- Additional members of the CARGO Board of Directors are listed below; full bios are available on the CARGO website .
